Background and Purpose-Lower serum low-density lipoprotein cholesterol (LDL-C) levels have been associated with increased risk of death after intracerebral hemorrhage (ICH). Nevertheless, their link with hematoma growth (HG) is unknown. Therefore, we aimed to investigate the relationship between LDL-C levels, HG, and clinical outcome in patients with acute ICH. Methods-We prospectively studied 108 consecutive patients with primary supratentorial ICH presenting within 6 hours from symptoms onset. National Institutes of Health Stroke Scale score and ICH volume on computed tomography scan were recorded at baseline and at 24 hours. Lipid profile was obtained during the first 24 hours. Significant HG was defined as hematoma enlargement Ͼ33% or Ͼ6 mL at 24 hours. Early neurological deterioration as well as mortality and poor long-term outcome (modified Rankin Scale score Ͼ2) at 3 months were recorded. 
I
ntracerebral hemorrhage (ICH) accounts for about 10% of strokes and is associated with poor outcome and high mortality rates. 1 Despite its devastating effects and social burden, no proven treatment has been consistently demonstrated to be effective in ameliorating ICH consequences. 2 Hematoma growth (HG) has been shown to be an independent determinant of death and disability after ICH, 3 and limiting HG represents the main target for emergent therapies for ICH. 2 HG occurs mainly during the first hours after ICH onset, most frequently within the first 6 hours. 4 -6 Besides earlier time to computed tomography (CT) scan, several factors have been related to HG, including larger baseline ICH volume, irregularly shaped hematoma, liver disease, alcohol consumption, higher systolic blood pressure, hyperglycemia, and hypofibrinogenemia. 6 -8 A post hoc analysis of the Recombinant Activated Factor VII Intracerebral Hemorrhage Trial showed that lower serum total cholesterol (total-C) levels were related to HG. 8 Decreased low-density lipoprotein cholesterol (LDL-C) 9 and total-C 10 -12 levels have been previously demonstrated to be associated with a higher risk of ICH. Moreover, both lower total-C and LDL-C levels have been shown to increase risk of death after ICH in several studies. 11, [13] [14] [15] Although lower cholesterol levels have been involved in the destruction of smooth muscle cells in arterial media promoting active bleeding, 16 the link between LDL-C levels, HG, and clinical deterioration in patients with acute ICH remains largely unknown.
The aim of the present study was to investigate the relationship between LDL-C levels and HG in patients with acute ICH and their impact on clinical outcome.
Subjects and Methods

Study Population
We prospectively evaluated consecutive patients with acute primary supratentorial ICH admitted to our emergency room within 6 hours from symptoms onset. A total of 142 patients were initially evaluated between April 2009 and June 2010. We excluded those patients who were under anticoagulant treatment (nϭ15), those with a Glasgow Coma Scale (GCS) score Ͻ8 (nϭ17), and those who underwent a surgical procedure (nϭ2). Finally, 108 patients were included in this study. The ethics committee approved all aspects of the study protocol.
CT Scan Protocol
All patients underwent 2 cranial CT scans: an initial CT scan on admission (Ͻ6 hours), and at 24 hours from symptoms onset (follow-up CT scan). All CT scans were performed according to the Neuroradiology Department protocol, with an image matrix of 340ϫ340, 1.5-mm-slice thickness.
ICH location (lobar or deep) and presence of intraventricular extension were recorded on initial CT scan. Hematoma volumes were calculated by 2 neuroradiologists blinded for clinical data on initial and follow-up CT scans using the formula ABC/2. 17 Most previous studies have used the threshold of 33% as the criterion for determining significant HG. 5 However, following the results of the study of Mayer et al, which showed significantly worse outcomes in patients who did not receive recombinant factor VIIa with an absolute mean increase of only 5.8 mL in the group treated with the highest dose, 18 recent works have also used the threshold of 6 mL. 19 Accordingly, we defined significant HG as hematoma enlargement Ͼ33% or Ͼ6 mL at 24 hours.
Clinical Assessment
On admission, body temperature, systolic and diastolic blood pressure, GCS score, and National Institute of Health Stroke Scale (NIHSS) score were obtained from all patients. GCS score, NIHSS score, and ICH volume at baseline were used as markers of ICH severity.
Early neurological deterioration (END) was defined as an increase of Ն4 points in NIHSS score or death at 24 hours from symptoms onset. Long-term outcome was assessed by means of the modified Rankin Scale (mRS) score at 3 months. We defined poor long-term outcome as mRS score Ͼ2. In patients with a baseline mRS score Ͼ2, we considered it poor long-term outcome when mRS score increased at least 1 point at 3 months.
Laboratory Parameters
The following routine laboratory tests were performed on admission: serum glucose, creatinine, hemoglobin, leukocyte count, platelet count, prothrombin time, activated partial thromboplastin time, and fibrinogen.
Serum albumin, total-C, LDL-C, high-density lipoprotein cholesterol, and triglyceride levels were determined in blood samples obtained within the first 24 hours from symptom onset, after a minimum of 12 hours fasting. LDL-C levels were calculated by Friedewald's formula. 20 When triglyceride levels were Ͼ300 mg/dL, LDL-C levels were measured by ultracentrifugation method.
Statistical Analysis
Descriptive and frequency statistical analysis were obtained and comparisons were made by use of the SPSS 17.0 (SPSS, Inc. 
Results
The main baseline characteristics are summarized in Table 1 . Mean time from symptom onset to initial CT scan was 169.2Ϯ84.2 minutes, and mean time to obtain lipid profile sample was 12.1Ϯ7.4 hours. Mean LDL-C levels were 109.2Ϯ31 mg/dL (102.4Ϯ28 mg/dL in statin users, and 110.3Ϯ31.4 mg/dL in nonusers), and mean triglyceride levels were 110.5Ϯ48.3 mg/dL (maximum value 270).
Of 108 patients, 14 patients did not have a follow-up CT scan (8 of them died Ͻ24 hours) and were excluded from HG analysis. HG occurred in 30 patients (31.9%) of 94 who had a follow-up CT scan. In these 94 patients, mean ICH volumes at baseline and at 24 hours were 20.8Ϯ21.8 mL and 25.8Ϯ29.2 mL, respectively, and mean HG was 5Ϯ9.7 mL. From the total sample, 22 patients (20.4%) experienced END. At 3 months, 83 patients (76.9%) had poor long-term outcome, including the 28 patients (25.9%) who died. Median time from onset to death was 3 (1-10) days. Of 28 patients who died within 3 months, 11 patients (39.3%) died within the first 48 hours, 8 patients (28.6%) between 48 hours and day 7, and 9 patients (32.1%) between day 7 and 3 months.
HG was significantly associated with both END (30% of patients who experienced HG deteriorated versus 3.1% of patients without HG; PϽ0.001), and 3-month mortality (40% of HG patients died versus 6.3% who did not experience HG; PϽ0.001), but not with poor long-term outcome (86.7% of HG patients had a poor long-term outcome versus 68.8% of no-HG patients; PϽ0.078).
Relationship Between LDL-C and Hematoma Growth
Potential predictors of HG are shown in Table 1 . HG patients had lower LDL-C (Figure) and total-C levels, as well as higher creatinine levels and greater ICH volume at baseline than no-HG patients. LDL-C levels were unrelated to ICH location (lobar 100.6Ϯ33.6 mg/dL versus deep 112.6Ϯ29.4 mg/dL; Pϭ0.110), and were lower in HG patients in both lobar (86.5Ϯ34.5 mg/dL versus 117.4Ϯ20.9 mg/dL; Pϭ0.010) and deep (103.9Ϯ32.7 mg/dL versus 117.3Ϯ27.4 mg/dL; Pϭ0.042) ICH.
Mean time from symptom onset to initial CT scan was 173.6Ϯ84.6 minutes in HG patients, and 167.9Ϯ83.8 minutes in no-HG patients (Pϭ0.688). Similarly, there were no significant differences in mean time from symptom onset to obtain lipid profile between HG and no-HG patients (11.9Ϯ7.4 hours versus 11.9Ϯ7.5 hours; Pϭ0.956).
Although LDL-C was unrelated to baseline ICH volume (rϭϪ0.18; Pϭ0.078), LDL-C levels were inversely correlated with the amount of hematoma enlargement at 24 hours (rϭϪ0.31; Pϭ0.004) and with 24-hour ICH volume (rϭϪ0.23; Pϭ0.033). A receiver operating characteristic curve identified LDL-C level Ͻ95 mg/dL as the value that better predicted HG (sensitivity, 86.9%; specificity, 60%). In contrast, total-C level Ͻ168 mg/dL, creatinine level Ͼ0.73 mg/dL, and baseline ICH volume Ͼ21.9 mL were the cut-off values that better discriminate between presence or absence of HG. In multivariate logistic regression analysis, LDL-C level Ͻ95 mg/dL (OR, 4.24; 95% CI, 1.26 -14.24; Pϭ0.020) and baseline ICH volume Ͼ21.9 mL (OR, 4.25; 95% CI, 1.14 -15.9; Pϭ0.032) emerged as independent predictors of HG. Using 25th-percentile cut-off points, low LDL-C level (Ͻ91 mg/dL; 25th percentile) remained a predictor of HG (OR, 9.17; 95% CI, 3.03-27.69; PϽ0.001).
Relationship Between LDL-C and Clinical Outcome
LDL-C levels were not correlated with markers of ICH severity at baseline including ICH volume (rϭϪ0.18; Pϭ0.078), GCS score (rϭ0.12; Pϭ0.255), and NIHSS score (rϭϪ0.17; Pϭ0.091). Similarly, patients pretreated with statins had similar [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] ; Pϭ0.548) at baseline than those without, respectively. END patients had lower GCS score and LDL-C level ( Figure) ; higher NIHSS score, glucose level, and baseline ICH volume; and more frequently had lobar location or intraventricular extension. At 3 months, patients with poor long-term outcome or who had died had older age, higher NIHSS score and glucose level, larger baseline ICH volume, and more frequently had intraventricular extension (Table 2 ). Lower LDL-C level was significantly associated with 3-month mortality, but not with poor long-term outcome (Figure) .
Multivariable logistic regression analysis showed that variables independently related to 3-month mortality were LDL-C level Ͻ95 mg/dL (OR, 6.34; 95% CI, When analyzing separately patients with 3-month mRS score 3 to 5 (nϭ55), LDL-C levels were comparable with those with mRS score Յ2 (nϭ25; 114.4Ϯ27.7 mg/dL versus 108.3Ϯ30.5 mg/dL; Pϭ0.388). Variables significantly associated with 3-month mRS score 3 to 5 were higher baseline NIHSS score (16 [11] [12] [13] [14] [15] [16] [17] [18] [19] 
Discussion
This study shows an association between serum LDL-C levels and risk of HG after an acute primary supratentorial ICH. LDL-C levels were inversely correlated and independently associated with HG at 24 hours. Moreover, lower LDL-C levels independently predicted END and 3-month mortality. However, in our series, LDL-C was unrelated to poor long-term outcome after acute ICH.
Previous studies focused on the relationship between serum cholesterol levels and risk of ICH have shown divergent results, 9 -12,21 but overall they suggest increasing ICH risk as LDL-C 9 and total-C 10 -12 levels decrease. This effect, however, appears to be unrelated to statin pretreatment in patients without previous stroke. 22, 23 In our study, an LDL-C level Ͻ95 mg/dL emerged as a powerful predictor of HG, END, and 3-month mortality. Although lower total-C levels have previously been reported to be related to HG 8 and lower LDL-C levels to 3-month mortality, 14, 15 to our knowledge, this is the first report on the relationship between LDL-C, HG, and END in patients with acute ICH.
Several factors may influence the relationship between LDL-C, HG, and clinical outcome. Although LDL-C might represent a marker of ICH severity rather than a predictor of HG or clinical outcome, in our series, LDL-C levels were unrelated to baseline ICH volume, GCS, and NIHSS scores. Moreover, LDL-C was inversely correlated with ICH volume at 24 hours, further supporting the relationship between LDL-C and HG. Conversely, statin pretreatment may potentially alter LDL-C levels. However, in our study, no relationship was found between statin pretreatment and HG or clinical outcome.
The mechanisms that explain the association of LDL-C and ICH are unclear. A possible explanation for this relationship would be the role of serum cholesterol levels for maintaining the integrity of vascular vessels. Lower cholesterol levels have been related to the development of medial smooth muscle cell necrosis, 16 thus decreasing the resistance to rupture of vascular wall. Moreover, cholesterol levels modify platelet aggregability by their action on the platelet activating factor, so that lower cholesterol levels may decrease platelet aggregation, 24, 25 thus predisposing to ICH growth.
This study has some limitations. Patients who were under anticoagulant treatment, those comatose, or who underwent a surgical procedure were excluded, which may underestimate the rate of END and poor outcome in our series. However, patients with these conditions usually receive different treatments than do those without, making difficult any comparison between them. In contrast, both HG and LDL-C were unrelated to poor long-term outcome, which may be explained in part by the relative small sample size and exclusion of patients who died before follow-up CT scan. Similarly, although no influence of LDL-C was found according to ICH location, it may be also explained in part by the relative small sample size. Therefore, larger studies are needed to elucidate the impact of LDL-C level depending on ICH location and on long-term outcome.
In conclusion, in patients with acute primary supratentorial ICH, low LDL-C level (Ͻ95 mg/dL) is an independent predictor of HG, END, and mortality at 3 months. However, LDL-C appeared unrelated to long-term outcome.
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